Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THC18 refers to a category of medical cannabis flower products standardized to contain approximately 18% delta-9-tetrahydrocannabinol (THC) by weight. These products are typically derived from specific cannabis strains and are used primarily for inhalation via vaporization. The main active ingredient is delta-9-tetrahydrocannabinol, the principal psychoactive cannabinoid in cannabis, which acts as a partial agonist at cannabinoid receptors CB1 and CB2 in the central nervous system. Medical indications include management of chronic pain, chemotherapy-induced nausea and vomiting, sleep disorders, anxiety-related disorders, and symptoms associated with multiple sclerosis such as spasticity and neuropathic pain[2][4][5]. The effects can include euphoria, relaxation, increased focus or sedation depending on strain composition. Side effects may include dry mouth, drowsiness, dizziness, changes in appetite or mood alterations[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on THC18.